|
Q2 FY2026
As of Jun 30, 2026
|
Q1 FY2026
As of Mar 31, 2026
|
Q4 FY2025
As of Dec 31, 2025
|
Q3 FY2025
As of Sep 30, 2025
|
Q2 FY2025
As of Jun 30, 2025
|
Q1 FY2025
As of Mar 31, 2025
|
Q4 FY2024
As of Dec 31, 2024
|
Q3 FY2024
As of Sep 30, 2024
|
Q2 FY2024
As of Jun 30, 2024
|
Q1 FY2024
As of Mar 31, 2024
|
Q4 FY2023
As of Dec 31, 2023
|
Q3 FY2023
As of Sep 30, 2023
|
Q2 FY2023
As of Jun 30, 2023
|
|
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Assets | |||||||||||||
| Investments, at fair value | |||||||||||||
| Non-controlled/unaffiliated investments | |||||||||||||
| Non-controlled/affiliated investments | |||||||||||||
| Controlled/affiliated investments | |||||||||||||
| Total investments, at fair value | |||||||||||||
| Cash and cash equivalents | |||||||||||||
| Foreign currency (amortized cost—$1,309 and $1,028, respectively) | |||||||||||||
| Receivable for investments sold and repaid | |||||||||||||
| Income receivable | |||||||||||||
| Expense support receivable | |||||||||||||
| Unrealized appreciation on foreign currency forward contracts | |||||||||||||
| Deferred financing costs | |||||||||||||
| Prepaid expenses and other assets | |||||||||||||
| Total assets | |||||||||||||
| Liabilities | |||||||||||||
| Payable for investments purchased | |||||||||||||
| Debt | |||||||||||||
| Unrealized depreciation on foreign currency forward contracts | |||||||||||||
| Shareholders’ distributions payable | |||||||||||||
| Organizational and offering costs payable | |||||||||||||
| Management fees payable | |||||||||||||
| Related Party | |||||||||||||
| Total management fees payable | |||||||||||||
| Subordinated income incentive fees payable | |||||||||||||
| Accrued capital gains incentive fee | |||||||||||||
| Related Party | |||||||||||||
| Total accrued capital gains incentive fee | |||||||||||||
| Administrative services expense payable | |||||||||||||
| Accrued accounting and administrative fees | |||||||||||||
| Interest payable | |||||||||||||
| Other accrued expenses and liabilities | |||||||||||||
| Total liabilities | |||||||||||||
| Series A Preferred Shares, $0.001 par value, unlimited shares authorized, 0 and 515 shares issued and outstanding, respectively; liquidation preference of $0 and $515, respectively | |||||||||||||
| Shareholders’ equity | |||||||||||||
| Common Shares, $0.01 par value, unlimited shares authorized, 57,284,588 and 51,837,481 Class I shares issued and outstanding, respectively | |||||||||||||
| Capital in excess of par value | |||||||||||||
| Retained earnings (accumulated deficit) | |||||||||||||
| Total shareholders’ equity | |||||||||||||
| Total liabilities and shareholders’ equity | |||||||||||||
| Net asset value per share of common shares at period end (in dollars per share) |
Loading...
